Jeena Sikho Lifecare Expands Ayurvedic Portfolio with Launch of Two New Wellness Products
Jeena Sikho Lifecare Limited has announced the domestic launch of two new Ayurvedic tablet formulations under the Acharya Ji's brand. The launch of Jeevanodya Vati and Ojavardhan Vati aims to strengthen the company's presence in the wellness and preventive healthcare segment.
Fredun Pharmaceuticals Launches PAWTALKS Digital Platform for Animal Healthcare
Fredun Pharmaceuticals has launched PAWTALKS, a specialized digital knowledge platform focused on the pet and animal healthcare ecosystem in India. The initiative aims to connect veterinary experts, researchers, and pet owners through social media channels like YouTube and Instagram to foster credible conversations and information sharing.
Natural Capsules Ltd Approves ₹10.01 Cr Fund Raise via Preferential Issue to Promoters
Natural Capsules Limited has approved a revised preferential issue of 1.12 lakh equity shares and 4.5 lakh convertible warrants to its promoter group. The transaction, valued at ₹10.01 Crore, aims to strengthen the company's capital base through immediate equity infusion and future warrant conversions.
Aurobindo Pharma Subsidiary Lannett Launches First US Inhalation Product in $908M Market
Aurobindo Pharma's subsidiary, Lannett Company LLC, has commercialised a generic version of Advair Diskus in the United States. This represents the company's entry into the complex US inhalation market, targeting a therapeutic area valued at nearly $1 billion.
Jeena Sikho Lifecare Expands Ayurvedic Portfolio with 9 New Wellness Product Launches
Jeena Sikho Lifecare Limited has announced the introduction of nine new Ayurvedic and healthcare products to its domestic portfolio. The expansion includes a novel Headache Relief Patch and eight specialized 500ml Arishta formulations targeting various wellness categories including heart, liver, and kidney care.
Lupin Subsidiary VISUfarma Signs ₹832 Cr Licensing Deal with Visus for YUVEZZI in Europe
Lupin Limited's wholly owned subsidiary, VISUfarma B.V., has secured exclusive commercialization rights for YUVEZZI, an innovative eye drop for presbyopia, across Europe and the UK. The agreement with Visus Therapeutics involves a total potential consideration of 75 million euros plus tiered royalties.
Wanbury Limited Secures EDQM Approval for Rivaroxaban API and Key USFDA Clearances
Wanbury Limited has achieved major regulatory milestones with EDQM approval for its Rivaroxaban API and USFDA DMF clearances for Paroxetine HCI and Metformin HCI. These approvals facilitate the company's expansion into high-demand regulated markets including the European Union and the United States.
Accent Microcell to Install 4.45 MW Wind Turbine to Slash Energy Costs and Boost Margins
Accent Microcell Limited is set to install a 4.45 MW Wind Turbine Generator through a turnkey partnership with Inox Wind Limited. The project focuses on captive power consumption to lower electricity costs at the company's existing manufacturing plants and its upcoming Phase-I of Plant-III.
Kwality Pharmaceuticals Targets ₹700 Crore Revenue in FY27 Following Guidance Revision
Kwality Pharmaceuticals has upwardly revised its FY27 revenue guidance to over ₹700 crore, reflecting a 40 percent year-on-year growth target. The company is strategically positioning itself to double its revenue to ₹1,500 crore by FY30, driven by aggressive international registrations and the commissioning of new manufacturing facilities.